دورية أكاديمية
أعرض في EDS

Oxylipin concentration shift in exhaled breath condensate (EBC) of SARS-CoV-2 infected patients.

التفاصيل البيبلوغرافية
العنوان: Oxylipin concentration shift in exhaled breath condensate (EBC) of SARS-CoV-2 infected patients.
المؤلفون: Borras E; Mechanical and Aerospace Engineering, University of California, Davis, One Shields Avenue, Davis, CA, United States of America.; UC Davis Lung Center, University of California Davis, Davis, CA, United States of America., McCartney MM; Mechanical and Aerospace Engineering, University of California, Davis, One Shields Avenue, Davis, CA, United States of America.; UC Davis Lung Center, University of California Davis, Davis, CA, United States of America.; VA Northern California Health Care System, 10535 Hospital Way, Mather, CA 95655, United States of America., Rojas DE; Mechanical and Aerospace Engineering, University of California, Davis, One Shields Avenue, Davis, CA, United States of America.; UC Davis Lung Center, University of California Davis, Davis, CA, United States of America., Hicks TL; Mechanical and Aerospace Engineering, University of California, Davis, One Shields Avenue, Davis, CA, United States of America.; UC Davis Lung Center, University of California Davis, Davis, CA, United States of America., Tran NK; UC Davis Lung Center, University of California Davis, Davis, CA, United States of America.; Department of Pathology and Laboratory Medicine, UC Davis, Sacramento, CA, United States of America., Tham T; UC Davis Lung Center, University of California Davis, Davis, CA, United States of America.; Department of Internal Medicine, University of California, Davis, 4150 V Street, Suite 3400, Sacramento, CA 95817, United States of America., Juarez MM; UC Davis Lung Center, University of California Davis, Davis, CA, United States of America.; Department of Internal Medicine, University of California, Davis, 4150 V Street, Suite 3400, Sacramento, CA 95817, United States of America., Franzi L; UC Davis Lung Center, University of California Davis, Davis, CA, United States of America.; Department of Internal Medicine, University of California, Davis, 4150 V Street, Suite 3400, Sacramento, CA 95817, United States of America., Harper RW; UC Davis Lung Center, University of California Davis, Davis, CA, United States of America.; VA Northern California Health Care System, 10535 Hospital Way, Mather, CA 95655, United States of America.; Department of Internal Medicine, University of California, Davis, 4150 V Street, Suite 3400, Sacramento, CA 95817, United States of America., Davis CE; Mechanical and Aerospace Engineering, University of California, Davis, One Shields Avenue, Davis, CA, United States of America.; UC Davis Lung Center, University of California Davis, Davis, CA, United States of America.; VA Northern California Health Care System, 10535 Hospital Way, Mather, CA 95655, United States of America., Kenyon NJ; UC Davis Lung Center, University of California Davis, Davis, CA, United States of America.; VA Northern California Health Care System, 10535 Hospital Way, Mather, CA 95655, United States of America.; Department of Pathology and Laboratory Medicine, UC Davis, Sacramento, CA, United States of America.
المصدر: Journal of breath research [J Breath Res] 2023 Aug 07; Vol. 17 (4). Date of Electronic Publication: 2023 Aug 07.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, N.I.H., Extramural
اللغة: English
بيانات الدورية: Publisher: IOP Pub Country of Publication: England NLM ID: 101463871 Publication Model: Electronic Cited Medium: Internet ISSN: 1752-7163 (Electronic) Linking ISSN: 17527155 NLM ISO Abbreviation: J Breath Res Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Bristol, UK : IOP Pub.
مواضيع طبية MeSH: Oxylipins* , COVID-19*, Humans ; SARS-CoV-2 ; Breath Tests/methods ; Metabolomics/methods ; Biomarkers/metabolism
مستخلص: Infection of airway epithelial cells with severe acute respiratory coronavirus 2 (SARS-CoV-2) can lead to severe respiratory tract damage and lung injury with hypoxia. It is challenging to sample the lower airways non-invasively and the capability to identify a highly representative specimen that can be collected in a non-invasive way would provide opportunities to investigate metabolomic consequences of COVID-19 disease. In the present study, we performed a targeted metabolomic approach using liquid chromatography coupled with high resolution chromatography (LC-MS) on exhaled breath condensate (EBC) collected from hospitalized COVID-19 patients (COVID+) and negative controls, both non-hospitalized and hospitalized for other reasons (COVID-). We were able to noninvasively identify and quantify inflammatory oxylipin shifts and dysregulation that may ultimately be used to monitor COVID-19 disease progression or severity and response to therapy. We also expected EBC-based biochemical oxylipin changes associated with COVID-19 host response to infection. The results indicated ten targeted oxylipins showing significative differences between SAR-CoV-2 infected EBC samples and negative control subjects. These compounds were prostaglandins A2 and D2, LXA4, 5-HETE, 12-HETE, 15-HETE, 5-HEPE, 9-HODE, 13-oxoODE and 19(20)-EpDPA, which are associated with specific pathways (i.e. P450, COX, 15-LOX) related to inflammatory and oxidative stress processes. Moreover, all these compounds were up-regulated by COVID+, meaning their concentrations were higher in subjects with SAR-CoV-2 infection. Given that many COVID-19 symptoms are inflammatory in nature, this is interesting insight into the pathophysiology of the disease. Breath monitoring of these and other EBC metabolites presents an interesting opportunity to monitor key indicators of disease progression and severity.
(© 2023 IOP Publishing Ltd.)
References: Signal Transduct Target Ther. 2021 Dec 16;6(1):427. (PMID: 34916489)
Biochem Pharmacol. 2022 Oct;204:115210. (PMID: 35973581)
Biochem Int. 1990;21(3):573-9. (PMID: 2222499)
Front Pharmacol. 2021 Sep 29;12:747450. (PMID: 34658883)
Metabolites. 2021 Dec 06;11(12):. (PMID: 34940605)
Immunol Allergy Clin North Am. 2007 Nov;27(4):587-96; v. (PMID: 17996577)
J Mol Diagn. 2021 Dec;23(12):1661-1670. (PMID: 34600137)
J Breath Res. 2021 Aug 19;15(4):. (PMID: 34343985)
Exp Lung Res. 2022 Apr-Aug;48(4-6):149-157. (PMID: 35708062)
Cell. 2020 Jul 9;182(1):59-72.e15. (PMID: 32492406)
J Biol Regul Homeost Agents. 2020 Sep 18;34(5):1629-1632. (PMID: 32945158)
J Breath Res. 2020 Jan 23;14(2):026001. (PMID: 31344695)
Front Med (Lausanne). 2021 Mar 17;8:604392. (PMID: 33816516)
Am J Pathol. 2020 Sep;190(9):1782-1788. (PMID: 32650004)
J Aerosol Sci. 2021 Feb;152:105693. (PMID: 33078030)
Commun Med (Lond). 2022 Dec 8;2(1):158. (PMID: 36482179)
Free Radic Biol Med. 2022 Feb 20;180:236-243. (PMID: 35085774)
J Breath Res. 2016 Dec 22;11(1):016001. (PMID: 28004639)
Clin Infect Dis. 2020 Apr 27;:. (PMID: 32338708)
Mod Pathol. 2020 Nov;33(11):2156-2168. (PMID: 32879413)
Methods Mol Biol. 2011;708:277-98. (PMID: 21207297)
Methods Mol Biol. 2007;406:409-36. (PMID: 18287705)
J Breath Res. 2021 Dec 20;16(1):. (PMID: 34852327)
Metabolites. 2022 Jul 04;12(7):. (PMID: 35888743)
Allergy. 2022 Aug;77(8):2337-2354. (PMID: 35174512)
Nature. 2020 May;581(7809):465-469. (PMID: 32235945)
J Breath Res. 2020 Jul 21;14(4):041001. (PMID: 32531777)
Trends Pharmacol Sci. 2002 May;23(5):232-7. (PMID: 12008001)
J Breath Res. 2019 Oct 03;13(4):046014. (PMID: 31349234)
J Breath Res. 2022 Jun 07;16(3):. (PMID: 35580553)
J Lipids. 2022 Jul 5;2022:8527305. (PMID: 35812307)
Natl Sci Rev. 2020 Jul;7(7):1157-1168. (PMID: 34676128)
J Breath Res. 2018 Jun 08;12(3):036020. (PMID: 29771240)
Expert Opin Ther Targets. 2022 Jan;26(1):13-28. (PMID: 35068281)
Environ Sci Technol. 2017 May 16;51(10):5737-5746. (PMID: 28406294)
Thorax. 2021 Jan;76(1):86-88. (PMID: 33097604)
Arch Med Res. 2021 Jan;52(1):107-120. (PMID: 32981754)
Anal Bioanal Chem. 2017 Nov;409(28):6523-6536. (PMID: 29063162)
Eur J Clin Pharmacol. 2022 Sep;78(9):1403-1420. (PMID: 35732963)
Biochim Biophys Acta. 1991 Jan 28;1081(2):174-80. (PMID: 1998735)
J Clin Invest. 1991 Apr;87(4):1139-45. (PMID: 2010530)
Arch Pharm (Weinheim). 2022 Mar;355(3):e2100367. (PMID: 34802171)
J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Sep 1;1061-1062:17-25. (PMID: 28697414)
J Breath Res. 2021 Jun 10;15(3):. (PMID: 34020435)
Immunol Allergy Clin North Am. 2018 Nov;38(4):667-678. (PMID: 30342587)
Cell Metab. 2020 Aug 4;32(2):188-202.e5. (PMID: 32610096)
معلومات مُعتمدة: I01 BX004965 United States BX BLRD VA; U18 TR003795 United States TR NCATS NIH HHS; UG3 OD023365 United States OD NIH HHS; U01 TR004083 United States TR NCATS NIH HHS; UH3 OD023365 United States OD NIH HHS; UL1 TR001860 United States TR NCATS NIH HHS; P30 ES023513 United States ES NIEHS NIH HHS
فهرسة مساهمة: Keywords: COVID 19; LC-qTOF; SARS-CoV-2; breath analysis; exhaled breath condensate (EBC); metabolomics
المشرفين على المادة: 0 (Oxylipins)
0 (Biomarkers)
تواريخ الأحداث: Date Created: 20230725 Date Completed: 20230808 Latest Revision: 20240118
رمز التحديث: 20240118
مُعرف محوري في PubMed: PMC10446499
DOI: 10.1088/1752-7163/acea3d
PMID: 37489864
قاعدة البيانات: MEDLINE
الوصف
تدمد:1752-7163
DOI:10.1088/1752-7163/acea3d